 Hydrazines
"Hydrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D006834
|
| MeSH Number(s) |
D02.442
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazines".
Below are MeSH descriptors whose meaning is more specific than "Hydrazines".
This graph shows the total number of publications written about "Hydrazines" by people in this website by year, and whether "Hydrazines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 3 | 5 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydrazines" by people in Profiles.
-
Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.
-
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
-
Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.
-
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
-
Riback JA, Bowman MA, Zmyslowski AM, Plaxco KW, Clark PL, Sosnick TR. Commonly used FRET fluorophores promote collapse of an otherwise disordered protein. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):8889-8894.
-
Prakash V, Tsekouras K, Venkatachalapathy M, Heinicke L, Pressé S, Walter NG, Krishnan Y. Quantitative Mapping of Endosomal DNA Processing by Single Molecule Counting. Angew Chem Int Ed Engl. 2019 03 04; 58(10):3073-3076.
-
Xu Y, Qi X, Zheng P, Berti CC, Liu P, Dong G. Deacylative transformations of ketones via aromatization-promoted C-C bond activation. Nature. 2019 03; 567(7748):373-378.
-
Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I?B. Mol Cancer Ther. 2018 12; 17(12):2564-2574.
-
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866.
-
Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor. . 2016 Jan; 15(1):60-71.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|